Abstract
Using quantitative deep HIV-1 sequencing in a subject who developed virological failure to deep salvage therapy with raltegravir, we found that most Q148R and N155H mutants detected at the time of virological failure originated from pre-existing minority Q148R and N155H variants through independent evolutionary clusters. Double 148R+N155H mutants were also detected in 1.7% of viruses at virological failure in association with E138K and/or G163R. Our findings illustrate the ability of HIV-1 to escape from suboptimal antiretroviral drug pressure through selection of pre-existing drug-resistant mutants, underscoring the importance of using fully active antiretroviral regimens to treat all HIV-1-infected subjects.
Copyright © 2010 Elsevier B.V. All rights reserved.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Amino Acid Sequence
-
Amino Acid Substitution* / drug effects
-
Amino Acid Substitution* / genetics
-
DNA Mutational Analysis
-
Drug Resistance, Viral* / drug effects
-
Drug Resistance, Viral* / genetics
-
HIV Infections / drug therapy*
-
HIV Infections / genetics*
-
HIV Infections / virology
-
HIV Integrase / metabolism
-
HIV Integrase Inhibitors / pharmacology*
-
HIV Integrase Inhibitors / therapeutic use*
-
HIV-1 / drug effects*
-
HIV-1 / enzymology
-
HIV-1 / genetics*
-
Humans
-
Male
-
Molecular Sequence Data
-
Mutation*
-
Phylogeny
-
Pyrrolidinones / pharmacology*
-
Pyrrolidinones / therapeutic use*
-
Raltegravir Potassium
-
Selection, Genetic* / drug effects
-
Treatment Failure
Substances
-
HIV Integrase Inhibitors
-
Pyrrolidinones
-
Raltegravir Potassium
-
HIV Integrase